Promising Advancements in enGene Holdings’ Clinical Trials Justify Buy Rating

Tip Ranks
2025.11.11 15:45
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Andres Y. Maldonado has maintained a Buy rating on enGene Holdings, setting a price target of $25.00, citing promising advancements in clinical trials. The Phase 2 LEGEND trial data shows improved response rates for detalimogene voraplasmid in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The treatment's safety, ease of use, and competitive pricing enhance its market potential. Additionally, Raymond James upgraded the stock to a Buy with a $27.00 price target, reflecting confidence in its future success.

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on enGene Holdings today and set a price target of $25.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising advancements in enGene Holdings’ clinical trials. The updated data from the Phase 2 LEGEND trial for detalimogene voraplasmid in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) demonstrates a significant improvement in response rates and durability. The complete response rate among patients has notably increased, showing a favorable comparison to other emerging therapies. Additionally, the treatment’s safety profile, ease of use, and potentially competitive pricing further strengthen its market potential.
The strategic protocol amendments have optimized patient outcomes and align with real-world urologic practices, enhancing both clinical applicability and regulatory credibility. The shift in primary endpoint to align with evolving regulatory standards also improves the likelihood of success in future filings. Furthermore, the non-viral, off-the-shelf administration of detalimogene is seen as transformative in the NMIBC treatment landscape, offering advantages over more complex viral therapies. These elements collectively reinforce the potential for detalimogene to become a leading community-scalable therapy, justifying the Buy rating.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Protara Therapeutics, and enGene Holdings. According to TipRanks, Y. Maldonado has an average return of 17.5% and a 51.92% success rate on recommended stocks.

In another report released today, Raymond James also upgraded the stock to a Buy with a $27.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.